LEXINGTON, Mass.--(BUSINESS WIRE)--Orphan Technologies, a Company dedicated to helping patients control their homocysteine levels, today recognizes Margaret G. McGlynn for receiving the Trailblazer Lifetime Achievement Award. Margaret McGlynn is a member of the Orphan Technologies Board of Directors, President of the HCU Network America and past President of Merck Vaccines. In addition, Ms. McGlynn is currently a Board Director at Vertex Pharmaceuticals, Amicus Therapeutics and Air Products.
“Margie McGlynn has a distinguished career filled with accomplishments in providing innovative medicines and support programs to help patients suffering from devastating diseases, in addition to novel vaccines to prevent disease,” commented J. Frank Glavin, CEO of Orphan Technologies. “The Trailblazer Lifetime Achievement Award is a fitting recognition of Margie’s contributions across the healthcare field. Margie’s contributions in the area of homocystinuria exemplify her leadership – she has dedicated her business acumen, time and energy to make a difference in the lives of patients suffering from homocystinuria, a rare genetic disease that affected her family. On behalf of Orphan Technologies, I would like to extend our warmest congratulations for this accolade and our thanks for her contributions to the homocystinuria community and Orphan Technologies.”
About Margaret McGlynn
Margaret (Margie) McGlynn is a biopharmaceutical executive with significant commercial leadership experience, who is now focused on developing new treatments and providing support for patients and families with homocystinuria, a rare genetic disease that affected her family. After receiving a dual degree in Pharmacy and MBA in Marketing, Margie spent 26 years at Merck where she served in leadership roles in marketing, new product development and managed care, last serving as President, Global Vaccines and Anti-Infectives. After leaving Merck, Margie then served for 4 years as President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), a Product Development Partnership which helps accelerate HIV vaccine development by bridging government and philanthropic funding with academic and industry vaccine research and development capabilities.
Margie is also the founder and President of the Hempling Foundation for Homocystinuria Research, which she established in 2009 to support research for new therapies to address homocystinuria. She is also a co-founder and current Board President of HCU Network America, a U.S. patient support group for patients with homocystinuria. Margie also serves on the boards of Air Products and Chemicals, Vertex Pharmaceuticals and Amicus Therapeutics.
About the PM 360 and the Trailblazer Lifetime Achievement Award
PM360 is a leading health-marketing industry trade magazine. Each year, PM360 honors the
pharmaceutical and medical device industries’ most influential innovators annually with the Trailblazer Awards. The Trailblazer Awards are given to outstanding companies, marketers, marketing teams, brand managers, and initiatives representing the best the industry has to offer. The Lifetime Achievement Award is an honor reserved for those who have made outstanding contributions throughout the course of a career.
About Orphan Technologies
Orphan Technologies is dedicated to developing novel therapies to dramatically improve the lives of patients suffering from the rare disorder, homocystinuria and related diseases. OT-58, our lead drug development candidate, has been optimized as an enzyme replacement therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases. For more information, please visit www.orphantechnologies.com